GlyCosmos Glycolipids
Glycolipid entries from the LIPID MAPS Structure Database (LMSD).
| Database | Last Updated |
|---|---|
| ChEBI | February 3, 2022 |
| KEGG | February 3, 2022 |
| LIPID MAPS Structure Database | February 3, 2022 |
| LipidBank | February 3, 2022 |
| PubChem | February 3, 2022 |
| Main Class | Sub Class | LM ID | Common Name ▲ | LipidBank ID | KEGG ID | PubChem CID | ChEBI ID | Exact Mass | Formula |
|---|---|---|---|---|---|---|---|---|---|
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/16:0)
|
1721.945137
|
C80H143N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/18:0)
|
1749.976437
|
C82H147N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/20:0)
|
1778.007737
|
C84H151N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/22:0)
|
1806.039037
|
C86H155N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/24:0)
|
1834.070337
|
C88H159N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/24:1(15Z))
|
1832.054687
|
C88H157N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/26:0)
|
1862.101637
|
C90H163N3O36
|
|||||
|
Neutral glycosphingolipids
|
Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)
|
Aleb(d18:1/26:1(17Z))
|
1860.085987
|
C90H161N3O36
|
|||||
|
Acylaminosugars
|
Heptaacylaminosugars
|
Alkalimonas delamerensis Lipid A Hepta-acyl form
|
1867.261264
|
C98H184N2O26P2
|
|||||
|
Acylaminosugars
|
Pentaacylaminosugars
|
Alkalimonas delamerensis Lipid A Penta-acyl form
|
1430.869619
|
C70H132N2O23P2
|
Displaying entries 151 - 160 of 6008 in total
To see the latest features, please visit our beta site.
International Collaboration
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Acknowledgements
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
